BRIEF-An Open Letter From Daniel O´Day Chairman CEO Gilead...

De Citoyens pour le climat
Révision datée du 12 juillet 2020 à 16:28 par RoscoeXgz12 (discussion | contributions) (Page créée avec « <br>June 29 (Reuters) - Gilead Sciences Inc:<br> <br>* AN OPEN LETTER FROM DANIEL O´DAY, CHAIRMAN & CEO, GILEAD SCIENCES<br> <br>* GILEAD SCIENCES INC - HAVE SET REMD... »)
(diff) ← Version précédente | Voir la version actuelle (diff) | Version suivante → (diff)
Sauter à la navigation Sauter à la recherche


June 29 (Reuters) - Gilead Sciences Inc:

* AN OPEN LETTER FROM DANIEL O´DAY, CHAIRMAN & CEO, GILEAD SCIENCES

* GILEAD SCIENCES INC - HAVE SET REMDESIVIR PRICE FOR GOVERNMENTS OF DEVELOPED COUNTRIES OF $390 PER VIAL

* GILEAD SCIENCES INC - IN U.S., SAME GOVERNMENT PRICE OF $390 PER VIAL FOR REMDESIVIR WILL APPLY

* GILEAD SCIENCES INC - PRICE FOR latterconsulting.pageride.com U.S.
PRIVATE INSURANCE COMPANIES, WILL BE $520 PER VIAL FOR REMDESIVIR

* GILEAD SCIENCES INC - ENTERED INTO AGREEMENT WITH HHS WHEREBY HHS AND STATES WILL CONTINUE TO MANAGE ALLOCATION TO HOSPITALS UNTIL END OF SEPT.

* GILEAD SCIENCES - MAJORITY OF PATIENTS ARE EXPECTED TO RECEIVE 5-DAY TREATMENT COURSE USING 6 VIALS OF REMDESIVIR, EQUATES TO $2,340/ PATIENT

* GILEAD SCIENCES INC - ONCE SUPPLIES OF REMDESIVIR ARE LESS CONSTRAINED, HHS WILL NO LONGER MANAGE ALLOCATION

* GILEAD SCIENCES INC - HAVE SET REMDESIVIR PRICE FOR GOVERNMENTS OF DEVELOPED COUNTRIES OF $390 PER VIAL

* GILEAD SCIENCES SAYS "AS WITH MANY OTHER ASPECTS OF THIS PANDEMIC, WE ARE IN UNCHARTERED TERRITORY IN PRICING REMDESIVIR"

* GILEAD SCIENCES - EXPECT INVESTMENT ON DEVELOPMENT AND MANUFACTURE OF REMDESIVIR TO EXCEED $1 BILLION (U.S.)

* GILEAD SCIENCES SAYS DISCOUNTED PRICE ON REMDESIVIR TO A LEVEL THAT IS AFFORDABLE FOR DEVELOPED COUNTRIES WITH LOWEST PURCHASING POWER Source text for Eikon: Further company coverage: